中药结合曼月乐治疗子宫内膜增生

Treatment of Endometrial Hyperplasia with Chinese Medicine combined with Mirena

目的探讨和分析中药结合曼月乐(左炔诺孕酮宫内节育系统)治疗子宫内膜增生的效果。方法研究选择2015年8月—2017年7月间在该院进行治疗的100例子宫内膜增生患者(经过子宫内膜病理诊断确诊为子宫内膜增生)当做研究对象,遵循患者的入院顺序分甲组、乙组,每组50例。所有患者均通过曼月乐进行治疗,而甲组患者加用中药进行治疗,评价甲乙两组患者的近期疗效、症状量化评分、子宫内膜厚度、血红蛋白水平、PBAC评分、血液流变学指标、性激素水平。结果甲组患者的近期疗效(94.0%)、周期量化评分(1.30±0.36)分、经期量化评分(0.97±0.21)分、经量量化评分(0.68±0.14)分、伴随症状量化评分(0.70±0.16)分、子宫内膜厚度(1.88±0.51)mm、血红蛋白水平(118.21±14.63)g/L、PBAC评分(32.75±5.43)分、红细胞聚集指数(1.64±0.32)、血浆黏度(1.10±0.16)m Pa/s、全血低切黏度(7.72±0.80)m Pa·s、全血高切黏度(3.50±0.38)m Pa·s、孕酮(19.68±3.82)μg/L、病理逆转率(90.0%)均明显优于乙组患者[(78.0%)、(2.42±0.62)分、(2.01±0.33)分、(1.59±0.31)分、(1.49±0.41)分、(4.23±0.91)mm、(107.52±10.27)g/L、(67.48±10.28)分、(2.07±0.51)、(1.34±0.21)m Pa·s、(9.65±1.05)m Pa·s、(3.82±0.43)m Pa·s、(15.35±2.38)μg/L、(74.0%)],差异有统计学意义(P<0.05)。甲组患者的黄体生成素(5.41±1.22)IU/L、卵泡刺激素(5.66±1.12)IU/L、雌二醇(44.81±7.12)ng/L同乙组[(5.31±1.18)IU/L、(5.51±1.05)IU/L、(45.53±7.26)ng/L]间的差异无统计学意义(P>0.05)。结论在子宫内膜增生患者的治疗中,曼月乐同中药联合应用的近期疗效确切,有效改善了患者的症状、子宫内膜厚度、血红蛋白水平、PBAC评分、血液流变学指标以及孕酮水平,应推广使用。

Objective This paper tries to investigate and analyze the traditional Chinese medicine combined with mirena(Levonorgestrel Intrauterine System)treatment of endometrial hyperplasia effect.Methods 100 cases of endometrial hyperplasia treated in this hospital(after endometrial pathological diagnosis of endometrial hyperplasia)from August 2015 to July 2017 were selected as the research objects,according to the patient’s admission order,they were divided into group A and group B,with 50 cases in each group.All patients were treated with mirena,and group A were treated with traditional Chinese medicine,the clinical efficacy,and evaluation of two groups of patients with symptoms score,endometrial thickness,hemoglobin level,PBAC score,blood rheology index,sex hormone level of the two groups were compared.Results Efficacy of group A was 94.0%,the periodic quantification score was(1.30±0.36)points,menstrual quantification score was(0.97±0.21)points,and quantified score was(0.68±0.14)points,concomitant symptom quantification score was(0.70±0.16)points,endometrial thickness was(1.88±0.51)mm,Hemoglobin level was(118.21±14.63)g/L,PBAC score was(32.75±5.43)points,red cell aggregation index was(1.64±0.32),plasma viscosity was(1.10±0.16)mPas,whole blood low cut viscosity was(7.72±0.80)mPa·s,high blood viscosity was(3.50±0.38)mPa·s,progesterone was(19.68±3.82)μg/L,pathological reversal rate was 90.0%,significantly better than group B of 78.0%,(2.42±0.62)points,(2.01±0.33)points,(1.59±0.31)points,(1.49±0.41)points,(4.23±0.91)mm,(107.52±10.27)g/L,(67.48±10.28)points,and(2.07±0.51),(1.34±0.21)mPa·s,(9.65±1.05)mPa·s,(3.82±0.43)mPa·s,(15.35±2.38)μg/L,(74.0%),with significant difference(P<0.05).The group of patients with luteinizing hormone of(5.41±1.22)IU/L,FSH of(5.66±1.12)IU/L,estradiol(44.81±7.12)ng/L,with group B[(5.31±1.18)IU/L,(5.51±1.05)IU/L,(45.53±7.26)ng/L,differences between the two groups were not statistically significant(P>0.05).Conclusion In the treatment of patients with endometrial hyperplasia,curative effect of traditional Chinese medicine combined with mirena application exactly,effectively improve the patient’s symptoms,endometrial thickness,hemoglobin level,blood rheology index,PBAC score and progesterone level,which should be promoted.